These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 39417110)

  • 1. Population dynamics of HIV drug resistance during treatment scale-up in Uganda: a population-based longitudinal study.
    Martin MA; Reynolds SJ; Foley BT; Nalugoda F; Quinn TC; Kemp SA; Nakalanzi M; Kankaka EN; Kigozi G; Ssekubugu R; Gupta RK; Abeler-Dörner L; Kagaayi J; Ratmann O; Fraser C; Galiwango RM; Bonsall D; Grabowski MK
    medRxiv; 2024 Oct; ():. PubMed ID: 39417110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High levels of pretreatment and acquired HIV drug resistance in Nicaragua: results from the first nationally representative survey, 2016.
    Girón-Callejas A; García-Morales C; Mendizabal-Burastero R; Román M; Tapia-Trejo D; Pérez-García M; Quiroz-Morales VS; Juárez SI; Ravasi G; Vargas C; Gutiérrez R; Romero L; Solórzano A; Sajquim E; Northbrook S; Ávila-Ríos S; Reyes-Terán G
    J Int AIDS Soc; 2019 Dec; 22(12):e25429. PubMed ID: 31860167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transitioning to Dolutegravir in a Programmatic Setting: Virological Outcomes and Associated Factors Among Treatment-Naive Patients With HIV-1 in the Kilombero and Ulanga Antiretroviral Cohort in Rural Tanzania.
    Ntamatungiro AJ; Eichenberger A; Okuma J; Vanobberghen F; Ndege R; Kimera N; Francis JM; Kagura J; Weisser M;
    Open Forum Infect Dis; 2023 Jul; 10(7):ofad321. PubMed ID: 37520425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 pretreatment and acquired antiretroviral drug resistance before tenofovir/ /lamivudine /dolutegravir (TLD) roll-out in Mozambique.
    Ismael N; Gemusse H; Mahumane I; Laurindo O; Magul C; Baxter C; Wilkinson E; Hofstra LM; Wagar N; Bila D; Mabunda N; da Silva J; Oliveira T; Raizes E; Preiser W; Manuel P; Ramos A; Vúbil A
    BMC Infect Dis; 2024 Jul; 24(1):748. PubMed ID: 39075381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of HIV Drug Resistance Mutations among Treatment-Naive People Living with HIV in a Tertiary Care Center in India.
    Srivastva S; Chakravarty J; Kushwaha AK
    Am J Trop Med Hyg; 2024 Apr; 110(4):713-718. PubMed ID: 38442417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretreatment resistance mutations and treatment outcomes in adults living with HIV-1: a cohort study in urban Malawi.
    Neuhann F; de Forest A; Heger E; Nhlema A; Scheller C; Kaiser R; Steffen HM; Tweya H; Fätkenheuer G; Phiri S
    AIDS Res Ther; 2020 May; 17(1):22. PubMed ID: 32434561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of WHO transmitted drug resistance mutations by deep sequencing in antiretroviral-naïve subjects in Hunan Province, China.
    Xiaobai Z; Xi C; Tian H; Williams AB; Wang H; He J; Zhen J; Chiarella J; Blake LA; Turenchalk G; Kozal MJ
    PLoS One; 2014; 9(6):e98740. PubMed ID: 24896087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired HIV drug resistance mutations on first-line antiretroviral therapy in Southern Africa: Systematic review and Bayesian evidence synthesis.
    Hauser A; Goldstein F; Reichmuth ML; Kouyos RD; Wandeler G; Egger M; Riou J
    J Clin Epidemiol; 2022 Aug; 148():135-145. PubMed ID: 35192922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment and Acquired Antiretroviral Drug Resistance Among Persons Living With HIV in Four African Countries.
    Crowell TA; Danboise B; Parikh A; Esber A; Dear N; Coakley P; Kasembeli A; Maswai J; Khamadi S; Bahemana E; Iroezindu M; Kiweewa F; Owuoth J; Freeman J; Jagodzinski LL; Malia JA; Eller LA; Tovanabutra S; Peel SA; Ake JA; Polyak CS;
    Clin Infect Dis; 2021 Oct; 73(7):e2311-e2322. PubMed ID: 32785695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in HIV-1 pretreatment drug resistance and HIV-1 variant dynamics among antiretroviral therapy-naive Ethiopians from 2003 to 2018: a pooled sequence analysis.
    Kiros M; Biset S; Gebremariam B; Yalew GT; Abegaz WE; Geteneh A
    Virol J; 2023 Oct; 20(1):243. PubMed ID: 37880705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trend of HIV-1 drug resistance in China: A systematic review and meta-analysis of data accumulated over 17 years (2001-2017).
    Zuo L; Liu K; Liu H; Hu Y; Zhang Z; Qin J; Xu Q; Peng K; Jin X; Wang JH; Zhang C
    EClinicalMedicine; 2020 Jan; 18():100238. PubMed ID: 31922125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temporal dynamics and drivers of durable HIV viral load suppression and persistent high- and low-level viraemia during Universal Test and Treat scale-up in Uganda: a population-based study.
    Rosen JG; Ssekubugu R; Chang LW; Ssempijja V; Galiwango RM; Ssekasanvu J; Ndyanabo A; Kisakye A; Nakigozi G; Rucinski KB; Patel EU; Kennedy CE; Nalugoda F; Kigozi G; Ratmann O; Nelson LJ; Mills LA; Kabatesi D; Tobian AAR; Quinn TC; Kagaayi J; Reynolds SJ; Grabowski MK
    J Int AIDS Soc; 2024 Feb; 27(2):e26200. PubMed ID: 38332519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Levels of Acquired HIV Drug Resistance Following Virological Nonsuppression in HIV-Infected Women from a High-Risk Cohort in Uganda.
    Segujja F; Omooja J; Lunkuse S; Nanyonjo M; Nabirye SE; Nassolo F; Bugembe DL; Bbosa N; Kateete DP; Ssenyonga W; Mayanja Y; Nsubuga RN; Seeley J; Kaleebu P; Ssemwanga D
    AIDS Res Hum Retroviruses; 2020 Sep; 36(9):782-791. PubMed ID: 32475121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporal dynamics and drivers of durable HIV viral load suppression and persistent high- and low-level viremia during Universal Test and Treat scale-up in Uganda: a population-based study.
    Rosen JG; Ssekubugu R; Chang LW; Ssempijja V; Galiwango RM; Ssekasanvu J; Ndyanabo A; Kisakye A; Nakigozi G; Rucinski KB; Patel EU; Kennedy CE; Nalugoda F; Kigozi G; Ratmann O; Nelson LJ; Mills LA; Kabatesi D; Tobian AAR; Quinn TC; Kagaayi J; Reynolds SJ; Grabowski MK
    medRxiv; 2023 Jun; ():. PubMed ID: 37398460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and characteristics of HIV drug resistance among antiretroviral treatment (ART) experienced adolescents and young adults living with HIV in Ndola, Zambia.
    Miti S; Handema R; Mulenga L; Mwansa JK; Abrams E; Frimpong C; Burke VM; Zulu M; Siwingwa M; Mwakazanga D; Kalibala S; Denison JA
    PLoS One; 2020; 15(8):e0236156. PubMed ID: 32804970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV transmission dynamics and population-wide drug resistance in rural South Africa.
    Gupta R; Kemp S; Kamelian K; Cuadros D; Gupta R; Cheng M; Okango E; Hanekom W; Ndung'u T; Pillay D; Bonsall D; Wong E; Tanser F; Siedner M
    Res Sq; 2023 Nov; ():. PubMed ID: 38076835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneity of the HIV epidemic in agrarian, trading, and fishing communities in Rakai, Uganda: an observational epidemiological study.
    Chang LW; Grabowski MK; Ssekubugu R; Nalugoda F; Kigozi G; Nantume B; Lessler J; Moore SM; Quinn TC; Reynolds SJ; Gray RH; Serwadda D; Wawer MJ
    Lancet HIV; 2016 Aug; 3(8):e388-e396. PubMed ID: 27470029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-level resistance to non-nucleos(t)ide reverse transcriptase inhibitor based first-line antiretroviral therapy in Ghana; A 2017 study.
    Parbie PK; Abana CZ; Kushitor D; Asigbee TW; Ntim NAA; Addo-Tetebo G; Ansong MRD; Ofori SB; Mizutani T; Runtuwene LR; Nishizawa M; Ishikawa K; Kiyono H; Ampofo WK; Matano T; Bonney EY; Kikuchi T
    Front Microbiol; 2022; 13():973771. PubMed ID: 36090108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High level of HIV drug resistance informs dolutegravir roll-out and optimized NRTI backbone strategy in Mozambique.
    Carnimeo V; Pulido Tarquino IA; Fuentes S; Vaz D; Molfino L; Tamayo Antabak N; Cuco RM; Couto A; Lobo S; de Amaral Fidelis J; Mulassua JS; Ciglenecki I; Ellman T; Schramm B
    JAC Antimicrob Resist; 2021 Jun; 3(2):dlab050. PubMed ID: 34223118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.